CRNX Crinetics Pharmaceuticals Inc

Rice Hall James & Associates LLC acquired 174,077 shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) during the third quarter, valued at approximately $7.25 million, marking a new position. Institutional investors now own about 98.51% of the company's stock. The company recently reported a quarterly EPS miss of ($1.38) against an expected ($1.27) and revenue of $0.14 million versus an estimated $0.39 million.

Crinetics Pharmaceuticals (CRNX) has seen a significant share price rebound, up 36% in the last three months, capturing the attention of biotech investors despite a negative year-to-date return. While the company trades at a premium 4.3x price-to-book ratio compared to the US pharmaceuticals average, suggesting market optimism for its future pipeline, a Discounted Cash Flow (DCF) model indicates the shares might be significantly undervalued. Investors face the question of whether the current valuation fully accounts for future growth or if further upside exists.

As ações da Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) caíram 8,1% após o anúncio da saída de sua Diretora Médica e de Desenvolvimento, Dra. Dana Pizzuti, a partir de 31 de dezembro de 2025. Dra. Pizzuti continuará como Consultora Estratégica até 31 de março de 2026 e depois como consultora com um pacote de indenização e benefícios, incluindo pagamento em dinheiro e aquisição de ações. A empresa é especializada no desenvolvimento de terapias para doenças endócrinas raras.

Squarepoint Ops LLC has significantly reduced its stake in Crinetics Pharmaceuticals (CRNX) by 69.8%, now holding 42,070 shares valued at $1.21 million. Despite this, analyst sentiment remains largely positive with a "Moderate Buy" consensus and a $77.55 price target. The article also details other institutional investor activities, insider selling, and the company's financial performance.

Crinetics Pharmaceuticals announced that its CEO, Dr. Scott Struthers, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 9:45 a.m. Pacific Time. The company, known for developing therapies for endocrine diseases and tumors, highlights increased visibility and investor engagement from this event. Their leading product, PALSONIFY™, is the first FDA-approved oral treatment for acromegaly, and they maintain a robust pipeline of over ten programs.

Crinetics Pharmaceuticals (CRNX) stock fell sharply after its Chief Medical and Development Officer, Dr. Dana Pizzuti, announced her departure effective December 31, 2025. Although Dr. Pizzuti will transition into an advisory role, the news spurred an 8% drop in share price due to investor uncertainty common in biotech regarding leadership changes. Despite the immediate market reaction, the company has several positive catalysts, including the recent FDA approval of PALSONIFY™ for acromegaly, multiple late-stage pipeline programs, and a strong cash position.